Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer.

Frontiers in immunology·2026

Same author

AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy.

Cell·2026

Same author

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas.

The New England journal of medicine·2026

Same author

Bioinspired oxidized mRNA lipid nanoparticles for ex vivo engineering of chimeric antigen receptor macrophages targeting solid tumors.

Bioengineering & translational medicine·2026

Same author

A generalizable system for antigenic peptide targeting across HLA-I allotypes.

bioRxiv : the preprint server for biology·2026

Same author

Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy.

The New England journal of medicine·2026

Search research articles

Related Experiment Video

Updated: May 5, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Chimeric antigen receptor therapy for cancer.

David M Barrett¹, Nathan Singh, David L Porter

¹Abramson Cancer Center and the Departments of Medicine, Pediatrics, and Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104;

Annual Review of Medicine

|November 27, 2013

Summary

Chimeric antigen receptor (CAR) therapies offer a new frontier in cancer treatment, combining targeted specificity with potent T cell-mediated cytotoxicity for improved patient outcomes.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Related Experiment Videos

Last Updated: May 5, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Area of Science:

Immunology
Synthetic Biology
Oncology

Background:

Targeted cancer therapies are crucial for improving patient outcomes by minimizing toxicity.
Advances in cellular immunology, synthetic biology, and cell processing enable novel therapeutic approaches.

Purpose of the Study:

To explore the potential of chimeric antigen receptor (CAR)-based therapies in cancer treatment.
To highlight the mechanisms and early clinical successes of CAR T-cell therapy.

Main Methods:

Chimeric antigen receptor (CAR)-based immunotherapy development.
Clinical trials evaluating CAR T-cell efficacy in various malignancies.
Research into optimizing tumor targets and enhancing CAR T-cell persistence.

Main Results:

CAR T-cell therapy has demonstrated significant antitumor activity in neuroblastoma, chronic lymphocytic leukemia, and B-cell lymphoma.
Ongoing trials are investigating CAR T-cell applications in a broader range of adult and pediatric cancers.

Conclusions:

CAR T-cell therapy represents a promising new avenue for targeted cancer treatment.
Further research is needed to identify optimal targets and enhance in vivo CAR T-cell expansion and persistence.